US FDA limits use of Covid-19 antibody therapies from Regeneron and Lilly
The US agency revised the EUAs for Lilly’s bamlanivimab plus etesevimab regimen, and Regeneron’s REGEN-COV, based on the…
US FDA rejects Merck’s chronic cough drug gefapixant
25 Jan 22Gefapixant is a non-narcotic selective P2X3 receptor antagonist intended for the treatment of refractory (RCC) or unexplained chronic…
US FDA approves remdesivir to treat non-hospitalised Covid-19 patients
24 Jan 22The US FDA has also expanded the emergency use authorisation of remdesivir to include the treatment of non-hospitalised…
APS gets FDA IND approval for APS03118 to treat different cancer types
24 Jan 22APS03118 is a new drug that targets patients with various advanced cancer types, caused by rearranged during transfection…
Amgen’s Lumakras approved in Japan to treat KRAS G12c-mutation positive NSCLC
21 Jan 22The MHLW approval was based on positive data from the Phase 2 CodeBreaK 100, a first-in-human, open-label multicentre…
Sputnik V shows superior antibody levels against Omicron variant
21 Jan 22People who received two doses of Sputnik V showed high levels of antibodies against Omicron than those vaccinated…
UCB to acquire epilepsy drugmaker Zogenix for up to $1.9bn
20 Jan 22The transaction will add Fintepla (fenfluramine), approved by the US Food and Drug Administration (FDA) and the European…
Biotechnology firm Altos Labs launches with $3bn funding
20 Jan 22Altos team contain scientists, clinicians, and leaders from both academia and industry, jointly working on reversing disease, injury,…
AstraZeneca’s STRIDE regimen shows positive survival outcomes in liver cancer trial
19 Jan 22The combination also showed no increase in severe liver toxicity and fewer discontinuations due to treatment-related adverse events…
Engitix raises $54m funding, collaborates with Dompé
19 Jan 22The Series A financing round was jointly led by existing investor Netherton Investments, alongside new investor Dompé farmaceutici